The Prevention and Management of Distant Metastases in Women with Breast Cancer
- 1 January 2007
- journal article
- review article
- Published by Taylor & Francis Ltd in Cancer Investigation
- Vol. 25 (1), 6-13
- https://doi.org/10.1080/07357900701226974
Abstract
About one-third of all women diagnosed with breast cancer face the risk of recurrence, which can occur at any stage of disease, observation time, and after any treatment modality. Most recurrence comes in the form of distant metastasis, which is the major cause of death in women with breast cancer. Treatments shown to decrease the risk of breast cancer recurrence, especially distant metastasis, will likely produce a survival benefit and a potentially significant improvement in quality of life in women with early breast cancer. New third-generation aromatase inhibitors (anastrozole, exemestane, and letrozole) that have been shown to be well tolerated have the potential to contribute to benefits beyond those seen with tamoxifen.Keywords
This publication has 42 references indexed in Scilit:
- breast cancer, earlyAnnals of Oncology, 2006
- Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of EpirubicinThe Oncologist, 2005
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases?European Journal Of Cancer, 2005
- Prognostic and Predictive Factors in Early-Stage Breast CancerThe Oncologist, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- The Genetic Basis of CancerScientific American, 1995